# EDGAR Filing Document

**Accession Number:** 0002108121
**File Stem:** 0001213900-26-059502
**Filing Date:** 2026-5
**Character Count:** 62022
**Document Hash:** 79665c202118adc161b698fe44df4dd1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-059502.hdr.sgml**: 20260520

**ACCESSION NUMBER**: 0001213900-26-059502

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 50

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260520

**DATE AS OF CHANGE**: 20260520

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ionetix Corp / DE /
- **CENTRAL INDEX KEY:** 0002108121
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **ORGANIZATION NAME:** 05 Real Estate & Construction
- **EIN:** 422828779
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-56821
- **FILM NUMBER:** 261003817

**BUSINESS ADDRESS:**
- **STREET 1:** THE GALLERIA, 2 BRIDGE AVENUE
- **STREET 2:** SUITE 241
- **CITY:** RED BANK
- **STATE:** NJ
- **ZIP:** 07701
- **BUSINESS PHONE:** 732-241-3073

**MAIL ADDRESS:**
- **STREET 1:** THE GALLERIA, 2 BRIDGE AVENUE
- **STREET 2:** SUITE 241
- **CITY:** RED BANK
- **STATE:** NJ
- **ZIP:** 07701

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** JDEV Acquisition Corp
- **DATE OF NAME CHANGE:** 20260128

?xml version='1.0' encoding='ASCII'? ck0002108121-20260331

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549**

**FORM 10-Q**

**☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended March 31, 2026

**☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from ______ to ______

Commission File Number: 000-56821

**IONETIX CORPORATION**

*(Formerly JDEV Acquisition Corp., a Nevada corporation)*

*(Exact name of registrant as specified in its charter)*

---

| | |
|:---|:---|
| Delaware | 41-2828779 |
| *(State or other jurisdiction of <br> incorporation or organization)* | *(I.R.S. Employer <br> Identification No.)* |

---

---

| |
|:---|
| 3130 Sovereign Drive, Lansing, MI 48911 |
| *(Address of principal executive offices, including zip code)* |

---

Registrant's telephone number, including area code: (517) 252-4069

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | |
|:---|:---|
| Large accelerated filer ☐ | Accelerated filer ☐ |
| Non-accelerated filer ☒ | Smaller reporting company ☒ |
|  | Emerging growth company ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 20, 2026, there were 105,421,312 shares of the registrant's common stock, par value $0.0001 per share, issued and outstanding.

**EXPLANATORY NOTE**

On April 9, 2026, subsequent to the fiscal quarter ended March 31, 2026, the fiscal quarter to which this Quarterly Report on Form 10-Q (this "Report") relates, JDEV Acquisition Corp., a Nevada corporation that is our predecessor ("JDEV"), consummated the previously announced transactions contemplated by the Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), by and among JDEV, JDEV Merger Subsidiary, a Delaware corporation and wholly owned subsidiary of JDEV ("Merger Sub"), and Ionetix Corporation, a Delaware corporation ("Ionetix"). The Merger Agreement provided for the acquisition of Ionetix by the registrant pursuant to the merger of Merger Sub with and into Ionetix (the "Merger"), with Ionetix continuing as the surviving corporation and a wholly owned subsidiary of the registrant.

In connection with the closing of the Merger, the registrant changed its name from JDEV Acquisition Corp. to Ionetix Corporation. Unless stated otherwise, this Report contains information about JDEV before the Business Combination. References to the "Company," "our," "us" or "we" in this Report refer to JDEV before the consummation of the Business Combination or Ionetix Corporation after the Business Combination, as the context suggests.

Except as otherwise expressly provided herein, the information in this Report does not reflect the consummation of the Merger, which, as discussed above, occurred subsequent to the period covered hereunder.

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| [**PART I -- FINANCIAL INFORMATION**](#a_001) | **1** |
| [**Item 1.** Financial Statements (Unaudited)](#a_002) | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Condensed Balance Sheets as of March 31, 2026 (Unaudited) and December 31, 2025](#a_003) | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Condensed Statements of Operations for the three months ended March 31, 2026 (Unaudited)](#a_004) | 2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Condensed Statements of Changes in Stockholders' (Deficit) Equity (Unaudited)](#a_005) | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Condensed Statements of Cash Flows for the three months ended March 31, 2026 (Unaudited)](#a_006) | 4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Notes to Condensed Unaudited Financial Statements](#a_007) | 5 |
| [**Item 2.** Management's Discussion and Analysis of Financial Condition and Results of Operations](#a_008) | 12 |
| [**Item 3.** Quantitative and Qualitative Disclosures About Market Risk](#a_009) | 15 |
| [**Item 4.** Controls and Procedures](#a_010) | 15 |
| [**PART II -- OTHER INFORMATION**](#a_011) | **16** |
| [**Item 1.** Legal Proceedings](#a_012) | 16 |
| [**Item 1A.** Risk Factors](#a_013) | 16 |
| [**Item 2.** Unregistered Sales of Equity Securities and Use of Proceeds](#a_014) | 16 |
| [**Item 3.** Defaults Upon Senior Securities](#a_015) | 16 |
| [**Item 4.** Mine Safety Disclosures](#a_016) | 16 |
| [**Item 5.** Other Information](#a_017) | 16 |
| [**Item 6.**](#a_018) [Exhibits](#a_018) | 16 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[SIGNATURES](#a_019) | 17 |

---

i

**PART I -- FINANCIAL INFORMATION**

**Item 1. Financial Statements.**

**Ionetix Corporation (fka JDEV Acquisition Corp.)** 

**CONDENSED BALANCE SHEETS**

*As of March 31, 2026 (Unaudited) and December 31, 2025*

---

| | | |
|:---|:---|:---|
|  | **March 31,<br> 2026** | **December 31, <br> 2025** |
|  | *(Unaudited)* |  |
| **Assets** |  |  |
| &nbsp;&nbsp;&nbsp;Cash | $10229 | $25490 |
| &nbsp;&nbsp;&nbsp;Total current assets | 10229 | 25490 |
| **Total Assets** | $**10229** | $**25490** |
| **Liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;Promissory Note Payable to Related Parties | $25000 | $25000 |
| &nbsp;&nbsp;&nbsp;Accrued Interest Payable | 377 | 69 |
| &nbsp;&nbsp;&nbsp;Total current liabilities | 25377 | 25069 |
| **Total Liabilities** | $**25377** | $**25069** |
| **Stockholders' (Deficit) Equity** |  |  |
| &nbsp;&nbsp;&nbsp;Common Stock, $0.0001 par value, 200,000,000 shares authorized; 5,500,000 shares issued and outstanding | $550 | $550 |
| &nbsp;&nbsp;&nbsp;Accumulated Deficit | (15698) | (129) |
| **Total Stockholders' (Deficit) Equity** | $**(15148)** | $**421** |
| **Total Liabilities and Stockholders' (Deficit) Equity** | $**10229** | $**25490** |

---

 

*The accompanying notes are an integral part of these condensed unaudited financial statements.*

**Ionetix Corporation (fka JDEV Acquisition Corp.)** 

**CONDENSED STATEMENTS OF OPERATIONS**

*(Unaudited)*

---

| | |
|:---|:---|
|  | **Three Months<br> Ended**<br>**March 31,<br> 2026** |
| **Revenue** | |
| &nbsp;&nbsp;&nbsp;Total Revenue | $- |
| **Operating Expenses** |  |
| &nbsp;&nbsp;&nbsp;Professional Services | $11597 |
| &nbsp;&nbsp;&nbsp;Filing Fees | 3569 |
| &nbsp;&nbsp;&nbsp;Bank Fees Expense | 95 |
| **Total Operating Expenses** | **15261** |
| **Other Income (Expense)** |  |
| &nbsp;&nbsp;&nbsp;Interest Expense | $(308) |
| **Total Other Income (Expense)** | **(308)** |
| **Net Loss** | $**(15569)** |
| **Per Share Data** |  |
| &nbsp;&nbsp;&nbsp;Weighted average number of common shares outstanding (basic and diluted) | 5500000 |
| &nbsp;&nbsp;&nbsp;Basic and diluted loss per share | $(0.00) |

---

 

*The accompanying notes are an integral part of these condensed unaudited financial statements.*

**Ionetix Corporation (fka JDEV Acquisition Corp.)** 

**CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY**

*For the Period from December 31, 2025 through March 31, 2026 (Unaudited)*

 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | | | |
|  | **Shares** | **Amount** | **Additional<br> Paid-in**<br>**Capital** | **Accumulated**<br>**Deficit** |<br>**Total** |
| **Balance at December 31, 2025 (Audited)** | **5500000** | **550** |  | **(129)** | **421** |
| Net loss for the three months ended March 31, 2026 | - | - |  | (15569) | (15569) |
| **Balance at March 31, 2026 (Unaudited)** | **5500000** | **550** |  | **(15698)** | **(15148)** |

---

 

*The accompanying notes are an integral part of these condensed unaudited financial statements.*

**Ionetix Corporation (fka JDEV Acquisition Corp.)** 

**CONDENSED STATEMENTS OF CASH FLOWS**

*(Unaudited)*

---

| | |
|:---|:---|
|  | **Three Months<br> Ended**<br>**March 31,<br> 2026** |
| **Cash Flows from Operating Activities** | |
| &nbsp;&nbsp;&nbsp;Net Loss | $(15569) |
| &nbsp;&nbsp;&nbsp;*Adjustments to reconcile net loss to net cash used in operating activities:* |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Changes in operating assets and liabilities:* |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase in accrued interest payable | 308 |
| **Net cash used in operating activities** | **(15261)** |
| **Cash Flows from Investing Activities** |  |
| &nbsp;&nbsp;&nbsp;**Net cash used in investing activities** | **-** |
| **Cash Flows from Financing Activities** |  |
| &nbsp;&nbsp;&nbsp;Proceeds from promissory notes | $- |
| &nbsp;&nbsp;&nbsp;Proceeds from issuance of common stock | - |
| &nbsp;&nbsp;&nbsp;**Net cash provided by financing activities** | **-** |
| **Net Change in Cash** | **(15261)** |
| Cash, Beginning of Period | $25490 |
| **Cash, End of Period** | $**10229** |
| *Supplemental Disclosure of Non-Cash Activities:* |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash paid for interest | $- |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash paid for income taxes | $- |

---

 

*The accompanying notes are an integral part of these condensed unaudited financial statements.*

**Ionetix Corporation (fka JDEV Acquisition Corp.)** 

**NOTES TO CONDENSED UNAUDITED FINANCIAL STATEMENTS**

*March 31, 2026*

**Note 1. Nature of Operations**

Ionetix Corporation, a Delaware corporation (formerly known as JDEV Acquisition Corp., the "Company"), was originally incorporated as JDEV Acquisition Corp. in the State of Nevada on November 26, 2025. The Company's management has chosen December 31st for its fiscal year end.

The Company was organized as a vehicle to investigate and, if such investigation warrants, acquire a target company or business seeking the perceived advantages of being a publicly held corporation. The Company's principal business objective is to achieve long-term growth potential through a combination with a business rather than immediate, short-term earnings. The Company is not restricted to any specific business, industry or geographical location and, thus, may acquire any type of business. The Company is a "shell company" as defined in Rule 12b-2 of the Exchange Act and a "blank check company" as that term is used in Section 7(b)(3) of the Securities Act of 1933, as amended.

On February 4, 2026, the Company filed a registration statement on Form 10 with the Securities and Exchange Commission to register its common stock pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended. The registration statement became effective by lapse of time on April 5, 2026.

As of March 31, 2026, the Company had not commenced any operations and had not generated any revenue. As described in Note 8 -- Subsequent Events, on April 9, 2026, the Company completed a reverse merger transaction with Ionetix Corporation, a privately-held Delaware corporation, and concurrently changed its name to "Ionetix Corporation." Through the balance sheet date, the Company was a blank check shell company within the meaning of Rule 12b-2 under the Exchange Act.

**Note 2. Basis of Presentation and Summary of Significant Accounting Policies**

<u>Basis of Presentation</u>

The accompanying condensed unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and the rules and regulations of the U.S. Securities and Exchange Commission (the "SEC") for interim financial information. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the interim financial information have been included. Operating results for the three months ended March 31, 2026 are not necessarily indicative of the results that may be expected for any future interim period or for the fiscal year ending December 31, 2026. These financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company's registration statement on Form 10 for the period from inception (November 26, 2025) through December 31, 2025.

Because the Company was incorporated on November 26, 2025, there are no comparable prior-period financial statements for the three months ended March 31, 2025.

<u>Use of Estimates</u>

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

<u>Cash</u>

Cash is reported in the balance sheet at cost, which approximates fair value. The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents; the Company held no cash equivalents at the balance sheet date. All of the Company's cash, totaling $10,229, is held with a single financial institution.

<u>Income Taxes</u>

The Company adopted ASC 740, "Income Taxes," at its inception. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. See Note 4.

<u>Loss per Common Share</u>

The Company adopted ASC 260, "Earnings per Share," at its inception. Basic loss per share has been calculated by dividing the Company's net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted loss per share is calculated by dividing the Company's net loss available to common stockholders by the diluted weighted average number of shares outstanding for the period. The Company has no potentially dilutive securities outstanding as of March 31, 2026; accordingly, basic and diluted loss per share are equal for all periods presented.

The computation of basic and diluted loss per share for the periods presented is as follows:

---

| | |
|:---|:---|
|  | **Three Months<br> Ended<br> March 31,<br> 2026** |
| &nbsp;&nbsp;&nbsp;Net loss attributable to common stockholders | $(15569) |
| &nbsp;&nbsp;&nbsp;Weighted average common shares outstanding -- basic and diluted | 5500000 |
| **Basic and diluted loss per share** | $**(0.00)** |

---

The Company is the legal acquirer in the reverse merger described in Note 8. Upon the closing of the Merger on April 9, 2026, all outstanding options to purchase shares of Ionetix common stock and all outstanding warrants to purchase shares of Ionetix common or preferred stock were assumed by the Company and converted into options to purchase 6,935,626 shares and warrants to purchase 8,152,333 shares, respectively, of the Company's common stock. Such securities were not outstanding as of March 31, 2026 and accordingly were not considered in the diluted loss per share computation for any period presented.

<u>Emerging Growth Company</u>

The Company is an "emerging growth company," as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"), and has elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act. This election allows the Company to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. As a result of this election, the Company's financial statements may not be comparable to companies that comply with public company effective dates.

<u>Recently Issued Accounting Pronouncements</u>

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

<u>Liquidity and Going Concern</u>

The accompanying condensed unaudited financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the recoverability of assets and the satisfaction of liabilities in the normal course of business.

As of March 31, 2026, the Company is a blank check shell company that has not commenced operations or generated any revenue since inception. The Company has incurred cumulative losses from inception of $15,698, has working capital deficiency of $(15,148), stockholders' deficit of $(15,148), and cash of $10,229. Net cash used in operating activities for the three months ended March 31, 2026 was $(15,261). Due to the Company's status as a blank check shell company without revenue-generating operations, combined with its limited liquidity, management believes these conditions raise substantial doubt about the Company's ability to continue as a going concern for the twelve months following the date these financial statements are issued.

Management's plan to alleviate this substantial doubt has included obtaining additional financing through related-party advances and consummating a business combination with an operating company. On April 9, 2026, after the balance sheet date, the Company completed the reverse merger transaction with Ionetix Corporation described in Note 8 -- Subsequent Events. Concurrent with the closing of that transaction, the Company sold 10,777,268 shares of common stock in a private placement at $3 per share, for aggregate gross proceeds of approximately $32.3 million. Although these transactions have occurred subsequent to the balance sheet date, no adjustment has been recognized to these condensed unaudited financial statements. The accompanying condensed unaudited financial statements do not include any adjustments that might be required should the Company be unable to continue as a going concern.

**Note 3. Capital Stock**

<u>Common Stock</u>

As of March 31, 2026 and December 31, 2025, the Company had 200,000,000 shares of common stock, par value of $0.0001, authorized and 5,500,000 shares issued and outstanding. There were no issuances of common stock, stock splits, repurchases, or other equity transactions during the three months ended March 31, 2026.

<u>Voting Rights and Dividends</u>

Holders of the Company's common stock are entitled to one vote per share on all matters submitted to a vote of stockholders. The Company has not paid any cash dividends to date and does not anticipate paying dividends in the foreseeable future. The holders of common stock do not have cumulative voting rights or preemptive rights.

**Note 4. Income Taxes**

The Company has incurred net operating losses since inception. As of March 31, 2026, the Company has approximately $15,698 in gross net operating loss ("NOL") carry-forwards available to offset future taxable income, subject to the change in ownership provisions under Internal Revenue Code ("IRC") Section 382. Under current U.S. federal income tax law, NOLs generated after December 31, 2017 generally do not expire but may be used only to offset 80% of taxable income in any future year. Utilization of the NOL carry-forwards may also be subject to annual limitations imposed by IRC Section 382 following any ownership changes.

In accordance with ASC 740-10, the Company evaluates the realizability of its deferred tax assets each reporting period and records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be realized. In assessing the realizability of deferred tax assets, the Company considers all available positive and negative evidence, including, among other factors: (i) the Company's status as a blank check shell company with no commenced operations, no historical revenue, and recurring net losses since inception; (ii) the absence of any history of taxable income against which the NOL carry-forwards could be utilized; (iii) the substantial doubt about the Company's ability to continue as a going concern described in Note 6; (iv) the lack of objectively verifiable evidence of future taxable income; and (v) the anticipated limitations on the utilization of pre-Merger NOL carry-forwards under IRC Section 382 as a result of the change of control that occurred on April 9, 2026 in connection with the reverse merger transaction described in Note 8. Based on the weight of available evidence -- which consists predominantly of negative evidence that is objectively verifiable -- management has concluded that it is not more likely than not that the deferred tax assets will be realized. Accordingly, the Company has recorded a full valuation allowance against the entirety of its gross deferred tax assets at each balance sheet date presented. The net deferred tax asset position is $0 at March 31, 2026 and December 31, 2025, and no income tax benefit has been recognized in the condensed unaudited statements of operations for the three months ended March 31, 2026.

Management will reassess the realizability of the Company's deferred tax assets in future reporting periods. Significant positive evidence, such as a sustained pattern of profitable operations following the consummation of the Merger, may result in the partial or full release of the valuation allowance and the recognition of a corresponding income tax benefit in a future period. Any such release would be reflected as a non-cash income tax benefit in the period in which management's assessment changes. Further, the Company's ability to utilize NOL carry-forwards generated prior to April 9, 2026 is expected to be substantially limited under IRC Section 382 as a result of the ownership change effected by the Merger, which limitations have not yet been quantified.

As a result of the reverse merger transaction described in Note 8 -- Subsequent Events, a change of control of the Company occurred on April 9, 2026. The Company's ability to utilize any pre-Merger NOL carry-forwards is likely to be subject to substantial limitations under IRC Section 382 following such ownership change.

The components of the Company's net deferred tax assets are as follows:

---

| | | |
|:---|:---|:---|
|  | **March 31,<br> 2026** | **December 31,<br> 2025** |
| **Net deferred tax assets -- Non-current:** | | |
| &nbsp;&nbsp;&nbsp;Depreciation | $- | $- |
| &nbsp;&nbsp;&nbsp;Stock-based compensation |  |  |
| &nbsp;&nbsp;&nbsp;Expected income tax benefit from NOL carry-forwards | 3297 | 27 |
| &nbsp;&nbsp;&nbsp;Less: valuation allowance | (3297) | (27) |
| **Deferred tax assets, net of valuation allowance** | $**-** | $**-** |

---

As of March 31, 2026, the Company has approximately $15,698 in gross NOL carry-forwards available to offset future taxable income, subject to limitations under IRC Section 382. A full valuation allowance has been recorded against the gross deferred tax asset because management believes the future realization of the related tax benefits is uncertain.

The reconciliation of the U.S. federal statutory income tax rate to the Company's effective tax rate is as follows:

---

| | |
|:---|:---|
|  | **Three Months<br> Ended<br> March 31,<br> 2026** |
| Statutory federal income tax rate | 21.0% |
| Valuation allowance | (21.0)% |
| **Effective income tax rate, net** | **0.0%** |

---

**Note 5. Commitments and Related Party Transactions**

<u>Office Space</u>

The Company utilizes the office space and equipment of its management at no cost. The value of this contributed office space and equipment is not material to the financial statements.

<u>Notes Payable -- Stockholders</u>

On December 10, 2025, the Company issued promissory notes (the "Notes") to five stockholders of the Company, pursuant to which the Company agreed to repay the principal balance and accrued interest on the date that the Company's common stock is listed for trading on a nationally recognized exchange in the United States. The Notes bear interest at a rate of five percent (5%) per annum, payable on the maturity date of the Notes. The Notes were outstanding throughout the three months ended March 31, 2026 and remained outstanding as of the date of this Quarterly Report on Form 10-Q.

The Notes outstanding as of March 31, 2026 and December 31, 2025 are summarized below:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Principal** | **Accrued<br> Interest at<br> 3/31/2026** | **Accrued<br> Interest at<br> 12/31/2025** | **Total<br> Carrying<br> Amount at<br> 3/31/2026** |
| Chief Executive Officer | $5000 | $75 | $14 | $5075 |
| Director | 5000 | 75 | 14 | 5075 |
| Director | 5000 | 76 | 14 | 5076 |
| Other related-party stockholders | 10000 | 151 | 27 | 10151 |
| **Total notes payable -- related parties** | $**25000** | $**377** | $**69** | $**25377** |

---

Interest expense recognized on the Notes was $308 for the three months ended March 31, 2026. The Notes are presented as a current liability on the condensed balance sheets because the listing-of-securities trigger that determines the maturity date is outside the Company's control.

**Note 6. Concentrations of Risk**

The Company maintains its cash in a business checking account at Bank of America, N.A. The Federal Deposit Insurance Corporation ("FDIC") insures deposits at this institution up to $250,000. As of March 31, 2026, the Company's cash balance did not exceed the FDIC insured limit.

**Note 7. Segment Information**

The Company operates as a single reporting segment engaged in the exploration of its properties. The Chief Operating Decision Makers are the Company's Chief Executive Officer ("CODM") who evaluates company performance based on Net income (loss), determined in accordance with U.S. GAAP, and other non-financial measures to determine the economic viability of the Company's exploration properties. Assets and liabilities are not separately analyzed or reported to the CODM and are not used to assist in decisions surrounding resource allocation and assessment of segment performance. As such, an analysis of segment assets and liabilities has not been included in this financial information. The CODM uses the above measures to assess profitability and guide resource allocations

The CODM conducts monthly financial reviews, focusing on operational efficiency across the Company's operations. Investment decisions, including capital expenditures for exploration and property acquisitions, are made based on expected return on investment and regulatory considerations in the jurisdictions that the Company operates.

The following represents segment information for the Company's single operating segment, for the periods presented:

---

| | |
|:---|:---|
|  | **Three Months<br> Ended**<br>**March 31,<br> 2026** |
| Revenue | $- |
| Professional Services | 11597 |
| Filing Fees | 3569 |
| Bank Fees Expense | 95 |
| Other items | 308 |
| Loss | 15569 |

---

**Note 8. Subsequent Events**

The Company evaluated subsequent events and transactions that occurred after the balance sheet date through May 20, 2026, the date the condensed unaudited financial statements were available to be issued, for items that should potentially be recognized or disclosed in the condensed unaudited financial statements. Based upon this review, except as described below and elsewhere in these notes, the Company did not identify any subsequent events that would have required adjustment of, or disclosure in, the condensed unaudited financial statements.

 

*<u>Redomiciliation to Delaware</u>*

On April 8, 2026, following approval by the Company's board of directors and all of its pre-Merger (as defined below) stockholders, the Company redomiciled from the State of Nevada to the State of Delaware. On April 9, 2026, following approval by the Company's board of directors and all of its pre-Merger stockholders, the Company filed a Restated Certificate of Incorporation with the Secretary of State of the State of Delaware, through which it changed its name to "Ionetix Corporation," and the Company's board of directors adopted Amended and Restated Bylaws.

 

*<u>Reverse Merger with Ionetix Corporation</u>*

On April 9, 2026 (the "Closing Date"), the Company, JDEV Merger Subsidiary, a Delaware corporation and wholly-owned subsidiary of the Company formed on April 9, 2026 ("Merger Sub"), and Ionetix Corporation, a privately-held Delaware corporation engaged in the development of proprietary superconducting cyclotron technology used to produce medical and industrial isotopes ("Ionetix"), consummated the transactions contemplated by that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), pursuant to which Merger Sub merged with and into Ionetix (the "Merger"), with Ionetix continuing as the surviving corporation and a wholly-owned subsidiary of the Company. As a result of the Merger, the Company acquired the business of Ionetix and ceased to be a "shell company" within the meaning of Rule 12b-2 under the Exchange Act.

Pursuant to the Merger Agreement, at the effective time of the Merger, each share of Ionetix common stock and each share of each class of Ionetix preferred stock issued and outstanding immediately prior to the closing of the Merger was converted into the right to receive that number of shares of the Company's common stock equal to the number of such shares multiplied by 0.5014 (the "Conversion Ratio"). At closing, an aggregate of 90,182,873 shares of the Company's common stock were issued to the former stockholders of Ionetix in exchange for their Ionetix common shares and Ionetix preferred shares (the "Merger Shares"). In addition, the Company assumed all outstanding options to purchase shares of Ionetix common stock (converted into options to purchase an aggregate of 6,935,626 shares of the Company's common stock) and all outstanding warrants to purchase shares of Ionetix common or preferred stock (converted into warrants to purchase an aggregate of 8,152,333 shares of the Company's common stock), with the number of shares and exercise price per share in each case adjusted by the Conversion Ratio. The Merger is intended to qualify as a tax-free reorganization under Section 368(a) of the Internal Revenue Code of 1986, as amended.

*<u>Private Placement Offering</u>*

Contemporaneously with the closing of the Merger, on April 9, 2026 the Company sold 10,777,268 shares of its common stock in a private placement offering (the "Offering") at a purchase price of $3 per share, for aggregate gross proceeds of approximately $32.3 million (before deducting placement agent fees and offering expenses). The Offering was exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and Rule 506(b) of Regulation D promulgated thereunder, and was sold solely to "accredited investors," as defined in Regulation D. Network 1 Financial Securities, Inc. ("Network 1") acted as placement agent in connection with the Offering, and was issued Placement Agent Warrants to purchase an aggregate of 862,183 shares of the Company's common stock. The Company's former Chief Executive Officer and director, Vincent LaBarbara, served as Managing Director / Investment Banking of Network 1, and certain other former stockholders of the Company were affiliated with the placement agent. See Note 5 -- Commitments and Related Party Transactions.

 

*<u>Termination Agreement with an Investor</u>*

In April 2026, Ionetix entered into a termination agreement with an investor pursuant to which the make-whole right and certain other investor rights and related agreements were terminated in their entirety. In connection with the termination, the Company issued 277,696 shares of common stock to the investor as consideration.

 

*<u>Post-Closing Capitalization</u>*

Immediately following the Merger, the Offering and the issuance of the Additional Shares, the Company had up to 105,360,141 shares of common stock issued and outstanding, comprising approximately (i) 90,182,873 Merger Shares held by former Ionetix stockholders, (ii) 10,777,268 shares held by investors in the Offering, (iii) 4,400,000 shares held by persons who held shares of the Company's common stock prior to the Merger, and (iv) 277,696 Additional Shares issued to Lilly. The 5,500,000 shares of common stock outstanding as of March 31, 2026 were reduced to 4,400,000 shares immediately prior to the closing of the Merger as a result of share cancellations effected in connection with the Merger.

In addition, immediately following the Merger, the Company had outstanding options to purchase 6,935,626 shares of common stock, assumed warrants to purchase 8,152,333 shares of common stock and Placement Agent Warrants to purchase 862,183 shares of common stock.

 

*<u>Accounting Treatment</u>*

The Merger has been accounted for as a "reverse merger" or "reverse acquisition" for financial reporting purposes, with Ionetix deemed to be the acquirer for accounting purposes. Consequently, the assets and liabilities and the historical operations reflected in the Company's financial statements for periods after the closing of the Merger will be those of Ionetix and will be recorded at the historical cost basis of Ionetix. The Company's historical financial statements presented in this Quarterly Report on Form 10-Q, including the condensed unaudited financial statements as of and for the three months ended March 31, 2026, reflect the historical operations of the Company as a blank check shell company prior to the Merger. As a result of the issuance of shares of the Company's common stock in the Merger, a change in control of the Company occurred as of the Closing Date. The Company expects to file an amendment to its Current Report on Form 8-K initially filed on April 16, 2026 to include the required Ionetix financial statements and unaudited pro forma condensed combined financial information.

 

*<u>Treatment of Outstanding Stockholder Notes</u>*

As of the date of this Quarterly Report on Form 10-Q, the Company's $25,000 aggregate principal amount of promissory notes payable to its five pre-Merger stockholders, together with accrued and unpaid interest thereon, remain outstanding. The Notes mature, by their terms, on the date that the Company's common stock is listed for trading on a nationally recognized exchange in the United States. The Company's common stock is not currently listed on a national securities exchange.

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.**

The following discussion and analysis of the Company's financial condition and results of operations should be read in conjunction with the condensed unaudited financial statements and accompanying notes thereto included elsewhere in this Quarterly Report on Form 10-Q and the audited financial statements and notes thereto included in the Company's registration statement on Form 10 for the period from inception (November 26, 2025) through December 31, 2025. This discussion contains forward-looking statements that involve risks and uncertainties. The Company's actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors.

**Forward-Looking Statements**

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. Forward-looking statements can be identified by use of terminology such as "believe," "hope," "may," "anticipate," "should," "intend," "plan," "will," "expect," "estimate," "project," "positioned," "strategy," and similar expressions. These forward-looking statements are subject to risks and uncertainties that are beyond the Company's control, including the risks discussed under the heading "Risk Factors" in the Company's registration statement on Form 10 and in this Quarterly Report on Form 10-Q. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

**Overview**

The Company was incorporated in the State of Nevada on November 26, 2025 as a vehicle to investigate and, if such investigation warrants, acquire a target company or business seeking the perceived advantages of being a publicly held corporation. As of March 31, 2026 and through the date of this Quarterly Report on Form 10-Q, the Company is a blank check shell company that has not commenced operations and has not generated any revenue.

On February 4, 2026, the Company filed a registration statement on Form 10 with the SEC to register its common stock pursuant to Section 12(g) of the Exchange Act, which became effective by lapse of time on April 5, 2026. As described in Note 8 to the condensed unaudited financial statements, on April 9, 2026, after the balance sheet date, the Company completed a reverse merger transaction with Ionetix Corporation, a privately-held Delaware corporation, and concurrently (i) redomiciled from Nevada to Delaware, (ii) changed its name to "Ionetix Corporation," (iii) sold 10,777,268 shares of common stock in a $32.3 million private placement at $3 per share, and (iv) ceased to be a "shell company" within the meaning of Rule 12b-2 under the Exchange Act. Through the balance sheet date, the Company was a blank check shell company.

**Plan of Operations**

During the next 12 months, the Company anticipates incurring costs related to (i) the filing of Exchange Act reports and (ii) the post-Merger operations of the combined company. Following the closing of the Merger on April 9, 2026 and the related $32.3 million private placement offering, the Company's historical operations as a blank check shell ceased and the Company began continuing the existing business operations of Ionetix Corporation as the acquirer for accounting purposes. See "Liquidity and Capital Resources" and Notes 6 and 8 to the condensed unaudited financial statements.

**Results of Operations**

 

*<u>Three Months Ended March 31, 2026 Compared to Three Months Ended March 31, 2025</u>*

The Company was incorporated on November 26, 2025 and accordingly there is no comparable prior-period activity for the three months ended March 31, 2025.

<u>Revenue</u>

The Company is a blank check shell and has not generated any revenue since inception. The Company did not generate any revenue during the three months ended March 31, 2026.

<u>Operating Expenses</u>

Total operating expenses for the three months ended March 31, 2026 were $15,261. Operating expenses for the three months ended March 31, 2026 consisted of:

---

| | |
|:---|:---|
|  | **Three Months<br> Ended<br> March 31,<br> 2026** |
| Professional Services | $11597 |
| Filing Fees | $3569 |
| Bank Fees Expense | $95 |
| **Total Operating Expenses** | $**15261** |

---

Professional Services represent fees for audit services performed by the Company's independent registered public accounting firm and outside accounting consulting services. Filing Fees consist of EDGAR filing services in connection with the Company's Form 10 registration statement and other periodic and current reports filed with the SEC, as well as state filing and registered agent fees. Bank Fees Expense consists of wire transfer fees and external transfer fees incurred in the ordinary course of operating the Company's business checking account.

<u>Other Income (Expense)</u>

Other income (expense) for the three months ended March 31, 2026 consisted of $308 of interest expense recorded on the $25,000 promissory notes payable to stockholders.

<u>Net Loss</u>

Net loss for the three months ended March 31, 2026 was $15,569.

**Liquidity and Capital Resources**

As of March 31, 2026, the Company had cash of $10,229 and a working capital deficiency of $(15,148), compared to cash of $25,490 and working capital of $421 as of December 31, 2025. The Company's only source of cash since inception has been (i) $550 in proceeds from the issuance of common stock to its founder and (ii) $25,000 in proceeds from the issuance of promissory notes to its five stockholders. The Company has not generated any cash from operations since inception.

Cash used in operating activities for the three months ended March 31, 2026 was $(15,261), reflecting the net loss for the period of $(15,569), partially offset by a $308 non-cash increase in accrued interest payable on the Company's promissory notes. There were no investing or financing activities during the three months ended March 31, 2026.

The Company's management and stockholders have historically indicated their intent to advance funds on behalf of the Company as needed to comply with its Exchange Act reporting requirements and to fund the consummation of a business combination; however, no formal agreements were in effect between the Company and its management or stockholders requiring them to provide any such funds. As described in Note 8 to the condensed unaudited financial statements, on April 9, 2026, after the balance sheet date, the Company received aggregate gross proceeds of approximately $32.3 million from the sale of 10,777,268 shares of its common stock in a private placement offering completed concurrently with the closing of the Merger. See *Liquidity and Going Concern* in Note 1.

**Off-Balance Sheet Arrangements**

The Company has not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company's financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that would be considered material to investors.

**Critical Accounting Estimates**

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. The Company evaluates these estimates on an ongoing basis. Actual results could differ from these estimates. The Company has not identified any critical accounting estimates as of March 31, 2026.

**Recent Accounting Pronouncements**

See Note 2 to the condensed unaudited financial statements.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

As a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act and in Item 10(f)(1) of Regulation S-K, the Company is not required to provide the information required by this Item.

**Item 4. Controls and Procedures.**

<u>Evaluation of Disclosure Controls and Procedures</u>

The Company maintains disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to the Company's management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

In designing and evaluating the Company's disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Under the supervision and with the participation of the Company's management, including the Company's principal executive officer (who also serves as the Company's principal financial officer), the Company evaluated the effectiveness of its disclosure controls and procedures as of March 31, 2026. Based on that evaluation, the Company's principal executive officer (who also serves as the Company's principal financial officer) concluded that, as of March 31, 2026, the Company's disclosure controls and procedures were effective at the reasonable assurance level.

In reaching this conclusion, management considered the Company's status as a blank check company with no operating activities, the limited nature and volume of transactions occurring during the period, the direct involvement of the Company's principal executive and financial officer in the review and approval of all material transactions, and the engagement of qualified external advisors — including the Company's independent registered public accounting firm, outside legal counsel, and accounting advisors — to assist in the evaluation of complex or non-routine accounting matters.

<u>Changes in Internal Control over Financial Reporting</u>

There were no changes in the Company's internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

**PART II -- OTHER INFORMATION**

**Item 1. Legal Proceedings.**

From time to time, the Company may become party to various legal proceedings arising in the ordinary course of business. As of the date of this Quarterly Report on Form 10-Q, the Company is not a party to any material legal proceedings.

**Item 1A. Risk Factors.**

As a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act and in Item 10(f)(1) of Regulation S-K, the Company is not required to provide the information required by this Item. For a discussion of risk factors affecting the Company, see the Company's registration statement on Form 10. There have been no material changes to the risk factors disclosed in the Company's registration statement on Form 10, except as may be implicated by the proposed business combination described in Note 8 to the condensed unaudited financial statements and in Item 2 above.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

None.

**Item 3. Defaults Upon Senior Securities.**

None.

**Item 4. Mine Safety Disclosures.**

Not applicable.

**Item 5. Other Information.**

During the three months ended March 31, 2026, no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement" as those terms are defined in Item 408 of Regulation S-K.

**Item 6. Exhibits.**

---

| | |
|:---|:---|
| **Exhibit<br> Number** | Description |
| 31.1 | [Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. (Filed herewith.)](ea029027901ex31-1.htm) |
| 31.2 | [Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. (Filed herewith.)](ea029027901ex31-2.htm) |
| 32.1 | [Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (Furnished herewith.)](ea029027901ex32-1.htm) |
| 32.2 | [Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (Furnished herewith.)](ea029027901ex32-2.htm) |
| 101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Ionetix Corporation (fka JDEV Acquisition Corp.) |  |  |
| Date: May 20, 2026 |  |  |
|  | By: | */s/ Kevin Cameron* |
|  |  | Kevin Cameron |
|  |  | Chief Executive Officer |
|  |  | *(Principal Executive Officer)* |
|  | By: | */s/ Phieu Phun* |
|  |  | Phieu Phun |
|  |  | Chief Financial Officer |
|  |  | *(Principal Financial Officer)* |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER**

**PURSUANT TO RULE 13a-14(a) AND RULE 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF**

**1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Kevin Cameron, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Ionetix
Corporation (fka JDEV Acquisition Corp.);

2. Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal
control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter
in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal
control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee
of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability
to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 20, 2026

 

---

| |
|:---|
| */s/ Kevin Cameron* |
| Kevin Cameron |
| Chief Executive Officer |
| *(Principal Executive Officer)* |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER**

**PURSUANT TO RULE 13a-14(a) AND RULE 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF**

**1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Phieu Phun, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Ionetix
Corporation (fka JDEV Acquisition Corp.);

2. Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal
control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter
in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal
control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee
of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability
to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 20, 2026

 

---

| |
|:---|
| */s/ Phieu Phun* |
| Phieu Phun |
| Chief Financial Officer |
| *(Principal Financial Officer)* |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER**

**PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE**

**SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of Ionetix Corporation (fka JDEV Acquisition Corp.) (the "Company") for the quarterly period ended March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Kevin Cameron, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of the Company.

Date: May 20, 2026

 

---

| |
|:---|
| */s/ Kevin Cameron* |
| Kevin Cameron |
| Chief Executive Officer |
| *(Principal Executive Officer)* |

---

 

*A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.*

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER**

**PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE**

**SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of Ionetix Corporation (fka JDEV Acquisition Corp.) (the "Company") for the quarterly period ended March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Phieu Phun, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of the Company.

Date: May 20, 2026

 

---

| |
|:---|
| */s/ Phieu Phun* |
| Phieu Phun |
| Chief Financial Officer |
| *(Principal Financial Officer)* |

---

 

*A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.*